A recent study published in the Frontiers in Endocrinology journal showed that heart failure with preserved ejection fraction ...

However, the authors note that the pathway "now places increased emphasis on establishing all four pillars of guideline-directed medical therapy (GDMT) for HFrEF in the hospital, when possible, along ...

The device targets an estimated $3.7 billion market for HFrEF treatment, a significant opportunity that has piqued the interest of analysts and investors alike. The company has demonstrated strong ...

Heart Failure, Pathophysiology, Etiology, Reduced Ejection Fraction, Preserved Ejection Fraction, Revascularization, CABG, ...

UK: In a secondary analysis of the FINEARTS-HF randomized clinical trial, researchers found that finerenone, a novel ...

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...

CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese ...

Thus, therapeutic intervention of this vicious cycle by inhibiting the effects of sympathetic activation by the application of a β blocker is essential in the treatment of chronic heart failure.

In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.